The challenge arising from the cost of haemophilia care: An audit of haemophilia treatment at Auckland Hospital

New Zealand Medical Journal

Volumn 116, Issue 1180, 2003, Pages

  Harper, Paul ^a   Brasser, Mary ^a   Moore, Louise ^a   Teague, Lochie ^a   Pitcher, Lydia ^a   Ockelford, Paul ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; MONOFIX; PROTHROMBIN; PROTHROMBINEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; PROTHROMBIN COMPLEX CONCENTRATES; RECOMBINANT PROTEIN;

ADOLESCENT; ARTICLE; CHILD; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG INDICATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG UTILIZATION; HEALTH CARE FINANCING; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL AUDIT; NEW ZEALAND; QUALITY OF LIFE; RETROSPECTIVE STUDY; TREATMENT PLANNING; ADULT; ECONOMICS; MALE; STATISTICS;

ADULT; BLOOD COAGULATION FACTORS; CHILD; DRUG COSTS; FACTOR IX; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MALE; MEDICAL AUDIT; NEW ZEALAND; RECOMBINANT PROTEINS;

EID: 0642368370     PISSN: 11758716     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Jones P. The early history of haemophilia treatment: a personal perspective. Br J Haematol 2000;111:719-25.
2. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32.
3. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999;5:145-54.
4. Briet E, Peters M. The incidence of inhibitors in hemophilia A and the induction of immune tolerance. Adv Exp Med Biol 2001;489:89-97.
5. O'Connell N, Mc Mahon C, Smith J, et al. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors. Br J Haematol 2002;116:632-5.
6. Aledort LM, Miners A, Bohn R, et al. Economic aspects of haemophilia care. Haemophilia 1999;5:216-9.
7. United Kingdom Haemophilia Centre Directors' Organisation Executive Committee. Guidelines on therapeutic products to treat Haemophilia and other hereditary coagulation disorders. Haemophilia 1997;3:63-77
8. Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001;7:446-52.
9. van den Berg HM, Fischer K, Mauser-Bunschoten EP, et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001;112:561-5.
10. Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med 1998;244:515-22.
11. Giangrande P. Distribution and treatment of haemophiliacs. Haemophilia 1998;4 (suppl 1):1-2.